Abstract
Inflammatory bowel diseases (IBDs) are characterized by severe inflammation in the gastrointestinal tract. The TNF-alpha exerts a benefitial role against infections during IBDs, but the dysregulation of this cytokine constitutes a key factor to the triggering and maintenance of intestinal inflammation. Therefore, TNF-alpha neutralizing tools, such as the anti-TNF-alpha antibody Inflixima…